Lilly announces a $6.5 billion Houston plant

Eli Lilly announced on September 23, 2025 that it plans to build a $6.5 billion active pharmaceutical ingredient (API) plant at Generation Park in Houston, Texas, and that the site will be one of the facilities making orforglipron, the company's first oral, small molecule GLP-1 medicine ^[1]. The plant is the second of four new U.S. sites Lilly said it would announce in 2025, and it is expected to be operational within five years ^[1].

What Lilly announced

The Houston facility will produce ingredients for Lilly's pipeline of small molecule medicines across cardiometabolic health, oncology, immunology and neuroscience ^[1]. Lilly says it will create 615 permanent, high-wage jobs — engineers, scientists, operations staff and lab technicians — plus about 4,000 construction jobs, for a combined 4,615 ^[1]. Texas officials put the building at roughly 1 million square feet in Harris County and said Lilly received a $5.5 million Texas Enterprise Fund grant, with the project also approved under the state's Jobs, Energy, Technology and Innovation (JETI) program ^[2]. That program cuts property tax bills for companies in large counties that create at least 75 jobs and invest at least $200 million ^[7].

Lilly said it picked Generation Park from more than 300 applications, weighing workforce, incentives, utilities, transportation and business climate ^[1]. CEO David Ricks told Reuters the site "will make orforglipron primarily and some of the precursor materials that make up (the drug)," and that the pill will also be produced at a Lilly site in Indiana ^[6].

The GLP-1 pill behind the investment

Orforglipron is a once-daily pill that mimics the appetite-regulating GLP-1 hormone; unlike semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), it is a small molecule rather than a peptide injection ^[1][6]. Lilly said it expected to submit orforglipron to global regulators for obesity by the end of 2025 ^[1]. In a late-stage trial, the pill helped patients lose 12.4% of their body weight ^[6]. A Jefferies analyst estimated peak annual sales of about $25 billion, and Wall Street analysts said the drug could be a candidate for the FDA's new one- to two-month priority review process ^[6].

The sources quote Ricks slightly differently. Lilly's own release describes orforglipron's potential as "a metabolic health treatment," while CNBC quotes the same passage as "an obesity and type 2 diabetes treatment" ^[1][5]. Either way, no approval had been granted at the time of the announcement.

Why it matters for patients

Supply has been a real problem in this drug class. Lilly and Novo Nordisk both faced supply constraints on their weekly injections as U.S. demand surged ^[5]. A pill is easier and cheaper to make at scale than an injectable, and Lilly frames the Houston plant as a way to avoid a repeat of shortages if orforglipron is approved ^[5]. Ricks said onshoring this production would "shorten lead times for medicine to get to patients" and reduce reliance on foreign suppliers ^[7].

The timing caveat matters, though: the plant is expected to be operational within five years ^[1], so it will not affect availability of any medicine in the near term. Lilly said orforglipron would also be made at an existing Indiana site ^[6]. Whether the pill is approved, when it launches, what it will cost, and how insurance will cover it are not addressed in these announcements.

Context on the broader build-out: Lilly pledged at least $27 billion in February 2025 for four new U.S. plants, on top of $23 billion in investments since 2020 ^[5]. Houston is Lilly's eighth U.S. manufacturing facility announced since 2020 ^[1]. The push comes as President Donald Trump has threatened tariffs on imported pharmaceuticals to encourage domestic production ^[5][6].

What happens next

• Lilly said it planned to submit orforglipron for obesity to regulators by the end of 2025 ^[1].
• Lilly said it would announce the two remaining U.S. plant locations in 2025; the Virginia site, a $5 billion facility in Goochland County, was announced the prior week ^[1][6].
• All four new plants are expected to begin making medicines within five years ^[5].

Lilly's release notes these are forward-looking statements, and that cost, timing, capacity and staffing could all change ^[1].